Increased expression of microRNA-503 and reduced expression of kangai-1 in B-cell non-Hodgkin's lymphoma

  • Authors:
    • Jingjing Wu
    • Aimin Li
    • Pengyu Zhang
    • Zhenchang Sun
    • Lijuan Han
    • Feifei Nan
    • Li Geng
  • View Affiliations

  • Published online on: January 8, 2016     https://doi.org/10.3892/etm.2016.2971
  • Pages: 917-922
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to determine the expression levels of microRNA-503 (miR-503) and the tumor suppressor gene, kangai-1 (KAI1), in B‑cell non‑Hodgkin's lymphoma (B-NHL). A total of 45 patients with B-NHL (including 29 cases with stage III/IV disease and 16 cases with stage I/II disease) were enrolled in this study. In addition, 26 patients with reactive lymphoid hyperplasia (RLH) were enrolled as the control patients. Reverse transcription‑quantitative polymerase chain reaction was performed in order to measure the expression levels of miR‑503 in B‑NHL and RLH tissues, and to detect the expression levels of miR‑503 and KAI1 in peripheral blood samples. In addition, KAI1 expression levels in B‑NHL and RLH tissues were detected using western blotting and immunohistochemical analysis. The expression levels of miR‑503 were found to be significantly increased in the tissues and peripheral blood of B‑NHL patients when compared with those in RLH patients (P<0.05). However, KAI1 was strongly expressed in RLH tissues and weakly expressed in B‑NHL tissues. Furthermore, the expression levels of KAI1 were significantly decreased in the tissues and peripheral blood of B‑NHL patients when compared with those in the tissues and peripheral blood of RLH patients (P<0.05). The expression levels of miR‑503 in the tissues and peripheral blood of patients with stage III/IV B‑NHL were significantly higher compared with those with stage I/II B‑NHL (P<0.05). By contrast, the expression levels of KAI1 in stage III/IV B‑NHL tissues were significantly higher compared with those in stage I/II B‑NHL tissues (P<0.05). In conclusion, miR‑503 was highly expressed, whereas KAI1 was poorly expressed, in the tissues and peripheral blood of B-NHL patients. Thus, miR-503 may have an application as a novel therapeutic and diagnostic marker in B-NHL patients.
View Figures
View References

Related Articles

Journal Cover

March-2016
Volume 11 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu J, Li A, Zhang P, Sun Z, Han L, Nan F and Geng L: Increased expression of microRNA-503 and reduced expression of kangai-1 in B-cell non-Hodgkin's lymphoma. Exp Ther Med 11: 917-922, 2016
APA
Wu, J., Li, A., Zhang, P., Sun, Z., Han, L., Nan, F., & Geng, L. (2016). Increased expression of microRNA-503 and reduced expression of kangai-1 in B-cell non-Hodgkin's lymphoma. Experimental and Therapeutic Medicine, 11, 917-922. https://doi.org/10.3892/etm.2016.2971
MLA
Wu, J., Li, A., Zhang, P., Sun, Z., Han, L., Nan, F., Geng, L."Increased expression of microRNA-503 and reduced expression of kangai-1 in B-cell non-Hodgkin's lymphoma". Experimental and Therapeutic Medicine 11.3 (2016): 917-922.
Chicago
Wu, J., Li, A., Zhang, P., Sun, Z., Han, L., Nan, F., Geng, L."Increased expression of microRNA-503 and reduced expression of kangai-1 in B-cell non-Hodgkin's lymphoma". Experimental and Therapeutic Medicine 11, no. 3 (2016): 917-922. https://doi.org/10.3892/etm.2016.2971